middle.news
Entropy Neurodynamics Reports 75% Response Rate in Phase 2a Trial of Oral Psilocybin Therapy for Treatment-Resistant IBS
9:34am on Monday 4th of May, 2026 AEST
•
Healthcare
Read Story
Entropy Neurodynamics Reports 75% Response Rate in Phase 2a Trial of Oral Psilocybin Therapy for Treatment-Resistant IBS
9:34am on Monday 4th of May, 2026 AEST
Key Points
75% response rate in treatment-resistant IBS patients
Mechanistic validation via psychological flexibility improvements
Safety profile consistent with psychedelic-assisted therapy
Supports advancement of IV psilocin formulation TRP-8803
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Entropy Neurodynamics (ASX:ENP)
OPEN ARTICLE